Why the study?
Do serum biomarkers and imaging modalities enhance the early detection of cancer therapeutics-related cardiac dysfunction in adults undergoing anticancer therapy?
Do serum biomarkers and imaging modalities enhance the early detection of cancer therapeutics-related cardiac dysfunction in adults undergoing anticancer therapy?
This review highlights the utility of combining serum biomarkers and advanced imaging techniques like strain echocardiography for the early detection of cardiotoxicity in cancer patients.
Answers are grounded in this paper and cite their sources.
Supports early cardiotoxicity monitoring with biomarkers and strain; leaves open prospective validation before practice change.
Significant advances have been made in detecting cancer therapeutics-related cardiac dysfunction with serum biomarkers, cardiovascular MRI, echocardiography and multi-modality approaches. Serum biomarkers, notably cardiac troponins and natriuretic peptides, have been evaluated for their prognostic ability in predicting left ventricular dysfunction. Imaging modalities, such as cardiovascular MRI and echocardiography, have been used for cardiac surveillance of patients with cancer undergoing chemotherapy. Developments in imaging, specifically myocardial deformation imaging, also known as strain, have been shown to be sensitive tools in detecting early changes in cardiac function. This review aims to synthesize the evidence that supports emerging serum biomarkers and complementary imaging modalities that continue to enhance the detection of cancer therapeutics-related cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Akhter et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: